Study registration: *
Publication Regev-Yochay G, Lancet Reg Health, 2021
Dates: 2020-12-19 to 2021-03-14
Funding: Not reported/unclear
Conflict of interest: no COI (GRY received grants for work on pneumococcal disease from Pfizer and for work on volatile organic compounds and COVID-19 form Nanosens. YK nothing to declare)

Methods

Study design:Cohort
Description of participants: Health care workers who have had a possible or confirmed exposure to a SARS-CoV-2-infected person and/or have any COVID-19-associated symptom
Inclusion criteria:
  • Health care workers of the of the Sheba Medical Center have had a possible or confirmed exposure to a SARS-CoV-2-infected person and/or have any COVID-19-associated symptom, including low grade fever, new cough, rhinorrhea, sore throat, myalgia, anosmia, ageusia or unexplained severe fatigue. Any exposure to a COVID-19 detected individual, whether at work, at home or in the community

Exclusion criteria:
  • participants exposed during the immediate post-first dose period (days 1-4)

Follow-up duration (months): 3
Vaccines:
  • 1 or 2 doses of BNT162b2
Variant description :
Variant name: Alpha
Evidence: Indirect evidence (prevalence of variant in the population: 10 to 99%)
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing stated: Yes, after publication to other investigators after approval of a proposal with a signed data access agreement
Data accessibility: available upon request
General comment *